NOVOMEDLINK™
  1. Activella®

    (estradiol/norethindrone acetate tablets)

  2. Vagifem®

    (estradiol vaginal tablets)

  3. GlucaGen® HypoKit®

    (glucagon [rDNA Origin] for injection)

  4. Levemir®

    (insulin detemir [rDNA origin] injection)

  5. Norditropin®

    (somatropin (rDNA origin) injection)

  6. NovoLog®

    (Insulin aspart [rDNA origin] injection)

  7. NovoLog® Mix 70/30

    (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])

  8. NovoSeven®

    (Coagulation Factor VIIa [Recombinant])

FlexPen® Is the World's #1 Selling Prefilled Insulin Pen2

Easy to teach. Easy to learn. Easy to use.

NovoLog® FlexPen® offers convenient delivery and features that fit many lifestyles.

FlexPen® is preferred over competitor's pen14

Randomized, multinational, open-label, two-way crossover (two 12-week periods) trial in 137 insulin-experienced patients with type 2 diabetes mellitus, comparing the efficacy of, safety of, and device preference for biphasic insulin aspart FlexPen® and a competitor pen. Satisfaction with pen devices was assessed using two device-specific questionnaires and a comparative questionnaire at end of study. Analysis — intent–to–treat ([ITT]; N=132) population with evaluable efficacy data.14

NovoLog® FlexPen® provides flexible delivery and easy dosing

  • Patients can take the disposable, prefilled pen anywhere — it's small enough to fit inside a purse or pocket
  • Once in use, NovoLog® FlexPen® can be used for up to 28 days without refrigeration
  • With accurate, dial-up dosing, it's easy to use and easy to learn
  • Patients can dial up their dose in one–unit increments for up to 60 units
  • One package contains five pens, totaling 1,500 U — so patients get more insulin than they would with a 1,000–U vial

  1. NovoLog® (insulin aspart [rDNA origin] injection) Indications and Usage

    NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

    NovoLog® Important Safety Information

    NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

    NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.

    Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.

    Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.

    Please see Prescribing Information.

Levemir®, NovoLog®, NovoLog® Mix 70/30, GlucaGen®, HypoKit®, and FlexPen® are registered trademarks of Novo Nordisk A/S. NovoSeven® and Norditropin® are registered trademarks of Novo Nordisk Health Care AG. Activella® 1.0 mg/0.5 mg, Activella® 0.5 mg/0.1 mg, and Vagifem® are registered trademarks of Novo Nordisk FemCare AG.